ERBB2 and cancer: One potential reason for this relationship might be that the outcomes of some patients with hormone receptor-positive, HER2-negative cancer might not be dependent on response to neoadjuvant chemotherapy, but depend on the effects of the endocrine therapy that they usually receive for 5 years or longer.25 This result highlights the importance of subtypes in prognostication and suggests that use of RCB for recurrence risk prediction after neoadjuvant therapy should be performed within a subtype-specific context.